Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 8, 2024
Efficient
and
site-specific
delivery
of
therapeutics
drugs
remains
a
critical
challenge
in
cancer
treatment.
Traditional
drug
nanocarriers
such
as
antibody-drug
conjugates
are
not
generally
accessible
due
to
their
high
cost
can
lead
serious
side
effects
including
life-threatening
allergic
reactions.
Here,
these
problems
overcome
via
the
engineering
supramolecular
agents
that
manufactured
with
an
innovative
double
imprinting
approach.
The
developed
molecularly
imprinted
nanoparticles
(nanoMIPs)
targeted
toward
linear
epitope
estrogen
receptor
alfa
(ERα)
loaded
chemotherapeutic
doxorubicin.
These
nanoMIPs
cost-effective
rival
affinity
commercial
antibodies
for
ERα.
Upon
specific
binding
materials
ERα,
which
is
overexpressed
most
breast
cancers
(BCs),
nuclear
achieved
receptor-mediated
endocytosis.
Consequentially,
significantly
enhanced
cytotoxicity
elicited
BC
cell
lines
overexpressing
paving
way
precision
treatment
BC.
Proof-of-concept
clinical
use
provided
by
evaluating
efficacy
sophisticated
three-dimensional
(3D)
models,
capture
complexity
tumor
microenvironment
vivo
without
requiring
animal
models.
Thus,
findings
highlight
potential
promising
class
novel
compounds
Pharmaceutics,
Год журнала:
2022,
Номер
14(8), С. 1722 - 1722
Опубликована: Авг. 17, 2022
Nature
is
the
largest
pharmacy
in
world.
Doxorubicin
(DOX)
and
paclitaxel
(PTX)
are
two
examples
of
natural-product-derived
drugs
employed
as
first-line
treatment
various
cancer
types
due
to
their
broad
mechanisms
action.
These
marketed
conventional
nanotechnology-based
formulations,
which
quite
curious
since
research
development
(R&D)
course
nanoformulations
even
more
expensive
prone
failure
than
ones.
Nonetheless,
nanosystems
cost-effective
represent
both
novel
safer
dosage
forms
with
fewer
side
effects
modification
pharmacokinetic
properties
tissue
targeting.
In
addition,
can
contribute
dose
modulation,
reversion
multidrug
resistance,
protection
from
degradation
early
clearance;
influence
mechanism
action;
enable
drug
administration
by
alternative
routes
co-encapsulation
multiple
active
agents
for
combined
chemotherapy.
this
review,
we
discuss
contribution
nanotechnology
an
enabling
technology
taking
clinical
use
DOX
PTX
examples.
We
also
present
other
approved
practice
containing
different
anticancer
drugs.
Cancers,
Год журнала:
2024,
Номер
16(11), С. 2012 - 2012
Опубликована: Май 25, 2024
Triple-negative
breast
cancer
(TNBC),
lacking
specific
receptors
found
in
other
subtypes,
poses
significant
treatment
challenges
due
to
limited
therapeutic
options.
Therefore,
it
is
necessary
develop
novel
approaches
for
TNBC.
In
the
last
few
decades,
many
attempts
have
been
reported
alternative
tools
TNBC
treatment:
immunotherapy,
radiotherapy,
targeted
therapy,
combination
and
nanotechnology-based
therapy.
Among
them,
therapy
show
most
promise
treatment.
This
review
outlines
recent
advancements
these
areas,
highlighting
efficacy
of
(immunotherapy
paired
with
chemotherapy,
or
radiotherapy)
both
preclinical
clinical
stages
therapies
utilizing
various
nanoparticles
loaded
anticancer
agents,
nucleic
acids,
immunotherapeutics,
CRISPRs
Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 8, 2024
Efficient
and
site-specific
delivery
of
therapeutics
drugs
remains
a
critical
challenge
in
cancer
treatment.
Traditional
drug
nanocarriers
such
as
antibody-drug
conjugates
are
not
generally
accessible
due
to
their
high
cost
can
lead
serious
side
effects
including
life-threatening
allergic
reactions.
Here,
these
problems
overcome
via
the
engineering
supramolecular
agents
that
manufactured
with
an
innovative
double
imprinting
approach.
The
developed
molecularly
imprinted
nanoparticles
(nanoMIPs)
targeted
toward
linear
epitope
estrogen
receptor
alfa
(ERα)
loaded
chemotherapeutic
doxorubicin.
These
nanoMIPs
cost-effective
rival
affinity
commercial
antibodies
for
ERα.
Upon
specific
binding
materials
ERα,
which
is
overexpressed
most
breast
cancers
(BCs),
nuclear
achieved
receptor-mediated
endocytosis.
Consequentially,
significantly
enhanced
cytotoxicity
elicited
BC
cell
lines
overexpressing
paving
way
precision
treatment
BC.
Proof-of-concept
clinical
use
provided
by
evaluating
efficacy
sophisticated
three-dimensional
(3D)
models,
capture
complexity
tumor
microenvironment
vivo
without
requiring
animal
models.
Thus,
findings
highlight
potential
promising
class
novel
compounds
